Epidemiology 1: Sample size calculation in randomized trials: Mandatory and mystical;Epidemiologie 1: Fallzahlschätzung in randomisierten studien: Ein muss und ein mysterium

Zeitschrift fur Arztliche Fortbildung und Qualitatssicherung

Volumn 100, Issue 2, 2006, Pages 129-135

  Schulz, Kenneth F ^a   Grimes, David A ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; SAMPLE SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEALTH CARE QUALITY; HUMAN; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STANDARD;

HUMANS; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE;

EID: 33645900256     PISSN: 14317621     EISSN: 16180992     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports or parallel-group trials. Lancet 2001;357:1191-4.
2. Altman DG, Schulz KF, Moher D et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
3. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 "negative" trials. N Engl J Med 1978;299:690-4.
4. Sackett DL, Cook DI. Can we learn anything from small trials? Ann NY Acad Sci 1993;703:25-31.
5. Pocock SJ. Clinical trials: a practical approach. Chichester: Wiley, 1983.
6. Meinert CL, Clinical trials: design, conduct, and analysis. New York: Oxford University Press, 1986.
7. Piantadosi S. Clinical trials: a methodologic perspective. New York: John Wiley and Sons, 1997.
8. Sinei SK, Schulz KF, Lamptey PR et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol 1990;97:412-9.
9. Matthews JN. Small clinical trials: are they all bad? Stat Med 1995;14:115-26.
10. Edwards SI, Lilford RJ, Braunholtz D, Jackson J. Why " underpowered" trials are not necessarily unethical. Lancet 1997;350:804-7.
11. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358-62.
12. Lilford RJ. The ethics of underpowered clinical trials. JAMA 2002;288:2118-9.
13. Chalmers TC, Levin H, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline, I: control of bias and comparison with large co-operative trials. Stat Med 1987;6:315-28.
14. Peto R. Failure of randomisation by 'sealed' envelope. Lancet 1999;354:73.
15. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
16. Schulz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456-8.
17. Walker MD. Atrial fibrillation and antithrombotic prophylaxis: a prospective meta-analysis. Lancet 1989;1:325-6.
18. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485.
19. Detsky AS, Sackett DL. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med 1985;145:709-712.
20. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ 1995;311:1621-5.
21. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev 1997;9:15-21.
22. Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr. Publication bias and clinical trials. Control Clin Trials 1987;8:343-53.
23. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405-8.
24. Chalmers I. Cardiotocography v Doppler auscultation: all unbiased comparative studies should be published. BMJ 2002;324:483-5.
25. Antes G, Chalmers I. Under-reporting of clinical trials is unethical. Lancet 2003;361:978-9.
26. Chalmers I. What do I want from health research and researchers when I am a patient? BMJ 1995;310:1315-8.
27. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994;121:200-6.
28. Peipert JF, Metheny WP, Schulz K. Sample size and statistical power in reproductive research. Obstet Gynecol 1995;86:302-5.
29. Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials. Chichester: John Wiley and Sons, 2002.
30. Wang SJ, Hung HM, Tsong Y, Cui L. Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. Stat Med 2001;20:1903-12.
31. Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics 1999;55:853-7.
32. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999;55:1286-90.
33. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990;9:65-71.
34. Fayers PM, Machin D. Sample size: how many patients are necessary? Br J Cancer 1995;72:1-9.
35. Chan AW, Hrobjartsson A, Haahr MT, Goetzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
36. Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet (in press).
37. Schulz KF, Grimes D. Sample size slip-pages in randomised trials: exclusions and the lost and wayward. Lancet 2002;359:781-5.
38. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet 2002;359:696-700.
39. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614-8.
40. Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet 2002;359:515-9.
41. Schulz KF, Grimes DA. Unequal group sizes in randomised trials: guarding against guessing. Lancet 2002;359:966-70.
42. Clarke M, Alderson P, Chalmers I. Discussion sections in reports of controlled trials published in general medical journals. JAMA 2002;287:2799-801.
43. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase: oral aspirin, both, or neither among 17.187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.